Sentences with phrase «study disease progression»
Development of a mouse model of lung chronic infection to study disease progression after NTMs infection and response to novel antibiotic therapies.
http://research.hsr.it/ Not exact matches
Amgen Executive Vice President of Research and Development Sean Harper said the study was designed to explore Kyprolis dosing regimens, noting that the the trial did not meet its goal in improving progression - free survival versus Velcade in patients who had not yet been treated for the disease.
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
For example, Eli Lilly & Co. (NYSE: LLY) has a phase 3 study of solanezumab under way in mild to moderate Alzheimer's disease patients that may slow disease progression by breaking up amyloid plaque buildups thought to be a major cause of the disease.
It offers cardio protection, it helps lower bad cholesterol, it may help prevent the progression of multiple sclerosis, it has the ability to regenerate brain cells after a stroke, it has the ability to cross the blood - brain barrier to potentially ward off Alzheimer's disease, apparently it's good at wiping amyloid plaque from the brain (which studies haves linked to Alzheimer's), it may help to prevent certain types of cancer, and studies have shown that it inhibits cancer cell growth and metastases (meaning it keeps cancer from spreading).
Some of the marketing material highlighted in Lion's cross claim includes: «A2 will improve human health through the consumption of a2 dairy milk products», «studies suggest that milk containing only the A2 type of protein may benefit you and your family if you're concerned with certain allergies, immune function or digestive wellbeing» and «there is significant evidence to suggest that beta casein A1 may be a primary risk factor for heart disease in adult men and also be involved in the progression of insulin dependent diabetes in children... Beta casein A1... is the most powerful risk factor ever discovered.»
One study, published in the «Journal of Alzheimer's Disease» in October 2013, found that the oil in coconut helps shield nerve cells from the toxic effects of protein plaques, which would otherwise drive Alzheimer's disease progrDisease» in October 2013, found that the oil in coconut helps shield nerve cells from the toxic effects of protein plaques, which would otherwise drive Alzheimer's disease progrdisease progression.
Not only was that assertion completely at odds with the uncertain state of the existing science, but it was contradicted by the study itself, in which Dr. McKee and her colleagues acknowledged that several other factors, besides prior participation in football, may influence CTE risk and disease severity, including factors other than cumulative hits to the head, and admitted that it was even «unclear» what roles concussions and repetitive subconcussive hits play in CTE risk, disease severity, and progression.
«By studying the ways different proteins like keratin dynamically change within a cell, we can better understand the progression of cancers and other diseases,» they say.
For researchers using mouse models to study a variety of cancers, including lymphoma, melanoma, breast, and prostate cancers as well as autoimmune and infectious diseases, the panel facilitates a highly sensitive and high - throughput investigation of biomarkers associated with disease progression.
The diagnosis of cancer and study of disease progression is often accomplished by examining a tumor sample containing many billions or even trillions of cells.
«This study shows that deflazacort may provide an important treatment for delaying the progression of the disease.»
SAMHD1 isn't a molecular «good guy» or «bad guy» per se, but there are cases in which blocking its activity might thwart disease progression, said Li Wu, the study's senior author and a professor of veterinary biosciences and microbial infection and immunity in Ohio State's Center for Retrovirus Research.
«This study is important, in part because we now have a new xenograft model that will for the first time allow us to apply new biomarkers to better predict disease progression and test new therapeutics.»
The new study, called FOR - DMD (Finding the Optimum Regimen of Corticosteroids for Duchenne Muscular Dystrophy), will determine whether daily steroid treatment or an alternative regime is more effective in slowing the disease progression and managing side effects.
In addition to suggesting that creatine could slow the progression of HD, these results also imply that neuroimaging may provide a useful biomarker of disease modification in studies of other potential treatments.
A report on the study, published in the September issue of Neurobiology of Disease, also suggest that finding ways to prevent the loss of serotonin or introducing a substitute neurotransmitter could slow or stop the progression of Alzheimer's disease and perhaps other demDisease, also suggest that finding ways to prevent the loss of serotonin or introducing a substitute neurotransmitter could slow or stop the progression of Alzheimer's disease and perhaps other demdisease and perhaps other dementias.
«The search for treatments that slow the progression of neurodegenerative diseases has gradually shifted from ameliorating symptoms to finding agents that reduce the progression of the disease,» said Gary Lynch, PhD, who studies neurodegeneration at the University of California, Irvine, and was not involved with this study.
«The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.
Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression.
Specifically, the Mount Sinai study was designed to test whether pharmacological compounds designed to block the function of XPO1 / CRM1 could stop disease progression in mouse models that exhibit some of the characteristics of MS. Researchers found that two chemical agents (called KPT - 276 and KPT - 350) prevented XPO1 / CRM1 from shuttling cargo out of the nucleus of nerve cells, which protected them from free radicals and structural damage.
Comparing his study to Surmeier's, Redmond noted: «One is an approach to try to minimize disease progression or maybe even get some recovery, the other is more aimed at the other end, after (dopamine - producing] cells are already dead.»
Study results suggest that pharmacological action on these epigenetic alterations may be helpful in slowing disease progression.
Redfield has a long history of publishing reports about his work: In 1988 he co-wrote a Scientific American feature article about early HIV research (available via subscription only), which emphasized the importance of studying the progression of HIV into AIDS, and of diagnosing the viral disease as early as possible.
Dr. Vaillancourt's study showed that a greater free water increase in the substantia nigra was associated with a decrease in dopamine neuron activity in one of these nearby regions, supporting the idea that free water changes are related to progression of the disease.
The studies not only point to the future possibility of specific microRNAs as a treatment for colorectal cancer, but also to the importance of external metabolic events conducted outside the cancer cell in the progression of the disease — factors that could someday be targeted to help slow metastasis, or even block it entirely.
Because environmental exposures have not had time to impact IBD progression in children, researchers have a clearer genetic picture of the disease allowing them to pick out additional genes overlooked in adult research, says senior study author Hakon Hakonarson, director of the Center for Applied Genomics at The Children's Hospital of Philadelphia.
He also notes that the study's results, because they are drawn from brains studied at a single point in time, can't illuminate disease progression.
«In our prospective cohort study, we evaluated the longitudinal association between changes in physical activity and disease progression in 137 patients with COPD and 26 patients with chronic bronchitis.»
«Age, gut bacteria contribute to MS disease progression, according to study.»
This study was designed to better define the process by which ALS progresses and to explore the role of brain motor neurons in disease development and progression.
Inhibiting NF - ƘB in microglia in mice slowed disease progression by 47 percent, says Brian Kaspar, MD, a principal investigator in the Center for Gene Therapy at Nationwide Children's and senior author of the new study.
But recent studies in both humans and lab mice have suggested that motor neurons in the brain — the upper motor neurons — may be involved in disease progression, although the extent and significance of this involvement has remained unknown.
The study results show that with a median (midpoint) follow - up of 20 months, 232 patients (75 percent) remained on therapy, 31 (10 percent) discontinued because of disease progression and 45 discontinued for other reasons (including 28 because of infection, eight for other adverse events and nine due to other medical events).
The study reports that Alzheimer's Disease and type 2 diabetes are so closely related that drugs currently used to control glucose levels in diabetes may also alleviate the symptoms and progression of Alzheimer's dDisease and type 2 diabetes are so closely related that drugs currently used to control glucose levels in diabetes may also alleviate the symptoms and progression of Alzheimer's diseasedisease.
Researchers at Rutgers Robert Wood Johnson Medical School published a study suggesting that gut bacteria at young age can contribute to Multiple sclerosis (MS) disease onset and progression.
«We're responsible for producing radio tracers: radioactive drugs that we use to study the imitation, onset and progression of disease in people,» Schaffer says in a teaser video previewing his lecture.
Meanwhile Coussens and her colleagues at U.C.S.F. found in a 2005 study, published in Cancer Cell, that the removal of antibody - making B cells from mice engineered to be prone to skin cancer prevented the tissue changes and angiogenesis that are prerequisites for disease progression.
Previous studies, he adds, have shown that taking testosterone at the wrong time — particularly by men with symptoms of active cancer progression who have not yet received testosterone - blocking therapy — can make the disease worse.
Researchers in the Jacobs School of Medicine and Biomedical Sciences at UB are continuing to study cerebral microbleeds, identified in the image above, as indicators of disease progression in multiple sclerosis.
«It could be that the treatment is causing inflammation that that looked like early disease progression, but we won't know without further studies,» Hodi said.
«The PALOMA - 3 study showed that palbociclib extends the time to progression of disease while maintaining very good quality of life.»
According to a 2011 study published in the New England Journal of Medicine, sirolimus in selected patients slowed the progression of the disease and was associated with a reduction in symptoms and improved quality of life.
A landmark clinical study in The Lancet provides convincing evidence that a frequently overlooked therapy for genetically - caused emphysema is effective and slows the progression of lung disease.
«Traditional methods of infectious disease research using animal models have provided limited information about disease progression until the study's endpoint, when investigators could analyze tissues from those animals,» he said.
This study offers another avenue to target and alter the disease progression.
Previous studies in humans suggest high - intensity exercise improves motor symptoms, but the evidence wasn't sufficient to determine whether exercise intensity modifies symptoms or disease progression.
«Previous pilot studies researching the use of DBS in Alzheimer's have indicated the potential to slow cognitive decline in some patients, and have even shown metabolic changes in the brain that may slow the progression of the disease.»
The technology has the added benefit of allowing investigators to study the progression of the disease over time.
Now a study has found that the gene mutation's toxic effects require higher than normal levels of a protein called suPAR to trigger the onset and progression of the disease.